Tumor heterogeneity is one of the major limiting factors to the efficacy of molecular targeted approaches including the CAR-T immunotherapy for reducing solid tumor. Recent effort to modify mesenchymal stem cells with a non-viral based proprietary platform technology for tumor site delivery of non-selective toxic metabolites has demonstrated its capability to significantly reduce tumor bulk in naturally occurring cancers within larger animals. Optimal bio-reagents and storage condition for cryopreservation, thawing, and hypothermic transportation of these modified cells to distant sites are crucial to offer high quality global distribution of modified MSCs for off-the-shelf therapy.
The team aims to develop bio-reagents and design processes for optimal cryopreservation and hypothermic transportation of modified MSCs to increase the technology readiness and accelerating global commercialization of viral-free therapeutic gene modification of MSCs.
Principal Investigator: A/Prof Too Heng-Phon
Institution: National University Health System
NHIC Ref: NHIC-I2D-1908233